CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Genocury Biotech, a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress platform, announced groundbreaking clinical data from its noval in vivo ...

This report describes a usually mild syndrome, dubbed LICATS, affecting about three-quarters of CAR T-cell recipients.